Viracta Therapeutics (NASDAQ:VIRX) Earns “Neutral” Rating from Rodman & Renshaw

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Rodman & Renshaw in a research note issued on Friday,Benzinga reports. They currently have a $0.25 target price on the stock, down from their prior target price of $3.50. Rodman & Renshaw’s price objective indicates a potential upside of 5.49% from the stock’s previous close.

Separately, Royal Bank of Canada cut their price target on Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.05.

Viracta Therapeutics Trading Down 5.2 %

Shares of VIRX stock opened at $0.24 on Friday. The firm’s 50 day moving average is $0.19 and its 200 day moving average is $0.32. The stock has a market capitalization of $9.42 million, a P/E ratio of -0.22 and a beta of 0.67. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31.

Institutional Trading of Viracta Therapeutics

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.